Cargando…

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease

OBJECTIVE: Clinical guidelines recommend weight loss to manage non-alcoholic fatty liver disease (NAFLD). However, the majority of patients find weight loss a significant challenge. We identified factors associated with engagement and adherence to a low-energy diet (LED) as a treatment option for NA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scragg, Jadine, Hallsworth, Kate, Taylor, Guy, Cassidy, Sophie, Haigh, Laura, Boyle, Marie, Anstee, Quentin, McPherson, Stuart, Avery, Leah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323391/ https://www.ncbi.nlm.nih.gov/pubmed/34326098 http://dx.doi.org/10.1136/bmjgast-2021-000678

Ejemplares similares

Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease
por: Scragg, Jadine, et al.
Publicado: (2020)

Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease
por: Karsdal, Morten A., et al.
Publicado: (2023)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping
por: Hallsworth, Kate, et al.
Publicado: (2021)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface
por: McPherson, Stuart, et al.
Publicado: (2023)

Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study
por: Hallsworth, Kate, et al.
Publicado: (2019)

Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
por: McPherson, Stuart, et al.
Publicado: (2020)

Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C
por: Hallsworth, Kate, et al.
Publicado: (2021)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)
por: Avery, Leah, et al.
Publicado: (2023)

Assessing the feasibility and acceptability of Changing Health for the management of prediabetes: protocol for a pilot study of a digital behavioural intervention
por: Cassidy, Sophie, et al.
Publicado: (2019)

Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy
por: Koo, Sara, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
por: Dyson, Jessica K, et al.
Publicado: (2014)

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
por: Jarvis, Helen, et al.
Publicado: (2022)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: Naimimohasses, Sara, et al.
Publicado: (2022)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway
por: Li, Meng, et al.
Publicado: (2018)

Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia
por: Chihota, Belinda Varaidzo, et al.
Publicado: (2022)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease
por: Neilson, Laura Jane, et al.
Publicado: (2021)

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
por: Wu, Heng, et al.
Publicado: (2016)

Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort
por: Olubamwo, Olubunmi O, et al.
Publicado: (2019)

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
por: Amin, Neeta B, et al.
Publicado: (2022)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6gt2i1v1ka55hol48h9jr9bgv2